PLx Pharma
11
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
27%
3 trials in Phase 3/4
55%
6 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Role: lead
Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.
Role: lead
Pharmacodynamic and Pharmacokinetic Study of PL-ASA
Role: lead
Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex
Role: lead
Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
Role: lead
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
Role: lead
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
Role: lead
Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
Role: lead
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Role: lead
Food-Effect Pharmacokinetic Study of PL2200
Role: lead
Ibuprofen-PC Compared With Ibuprofen in a GI Safety Trial
Role: lead
All 11 trials loaded